Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06154317
Status:
RECRUITING
Last Update Posted:
2023-12-04
First Post:
2023-11-23
Brief Title:
Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells and Study of the Bone Marrow Tumor Microenvironment Microenvironment of MM
Sponsor:
Centro di Riferimento Oncologico - Aviano
Organization:
Centro di Riferimento Oncologico - Aviano
Study Overview
Official Title:
Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells and Study of the Bone Marrow Tumor Microenvironment Microenvironment of MM
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple Myeloma MM is a hematologic cancer caused by the selective clonal expansion of plasma cells By acting on the microenvironment of the bone marrow MM shifts the niche balance and becomes chemoresistant due to its interaction with stromal cells Despite new therapeutic strategies MM still remains incurable and new strategies are urgently needed In order to successfully act on MM we must use a strategy that reflects its plasticity and blocks it on several targets proliferation interaction with the microenvironment and metastasis
The main interest of the project is to evaluate the effect of gene therapy identified in vitro directly on patient-derived samples in particular to translate the knowledge gained on myeloma cell lines in vitro to primary tumor cells taken from patients
The main interest of the project is to evaluate the effect of gene therapy identified in vitro directly on patient-derived samples in particular to translate the knowledge gained on myeloma cell lines in vitro to primary tumor cells taken from patients
Detailed Description:
Multiple Myeloma MM is a hematologic cancer caused by the selective clonal expansion of plasma cells By acting on the microenvironment of the bone marrow MM shifts the niche balance and becomes chemoresistant due to its interaction with stromal cells Despite new therapeutic strategies MM still remains incurable and new strategies are urgently needed In order to successfully act on MM we must use a strategy that reflects its plasticity and blocks it on several targets proliferation interaction with the microenvironment and metastasis
The main interest of the project is to evaluate the effect of gene therapy identified in vitro directly on patient-derived samples in particular to translate the knowledge gained on myeloma cell lines in vitro to primary tumor cells taken from patients
The main interest of the project is to evaluate the effect of gene therapy identified in vitro directly on patient-derived samples in particular to translate the knowledge gained on myeloma cell lines in vitro to primary tumor cells taken from patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None